BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.biocryst.com
Earnings Expectation
BioCryst Pharmaceuticals, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BCRX to report 3Q20 loss of $ 0.25 per share. For the full year, analysts anticipate top line of $ 31.88 million, while looking forward to loss of $ 0.93 per share bottom line.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
